Best Oncology Companies in Shanghai, China

Provider of discovery, development, production, and logistics services for of nuclear medicines. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals. It manufactures radiopharmaceutical drug products.

Funding rounds

• May 2026Series D$110M
• May 2026Conventional Debt$40M
• Sep 2025Series C$50M
• Sep 2025Conventional Debt$27M

Founders & team

HH TingCo-Founder And Chief Strategy OfficerHongHoi TingCo-FounderNicholas Lim WongCoo And Co-Founder

Investors

Prosperity7 Ventures, Sky9 Capital, Summer Capital, Chengwei Capital, Junson Capital, Guanghua Wutong Fund

Tech stack

Alibaba Cloud CdnAnimate.CssBaidu Analytics (百度统计)BootstrapJqueryNginx

Developer of immuno-therapeutics for cancer treatment. It offers CAR-T- based therapies and antibodies for the treatment of liver cancer, ovarian cancer, gastric cancer, cervical cancer, non-small cell lung cancer, and others.

Funding rounds

• Apr 2026Series D$110M
• Jan 2026Series C$70M
• Feb 2023Series B$45M
• Aug 2022Series B$125M

Founders & team

He XiaowenCo-Founder

Investors

RTW Investments, Qatar Investment Authority, Qiming Venture Partners, C&D, Quan Capital, Sinopharm Capital

Developer novel therapeutics for cancer. The company is focusing on developing innovative medicines in oncology and immunology. The company's pipeline include D3S-001 for the treatment of advanced unresectable or metastatic colorectal cancers.

Funding rounds

• Dec 2025Series B$108M
• Apr 2024Series A$62M
• Nov 2020Series A$200M

Founders & team

George ChenFounder & CEO

Investors

Medicxi, WuXi AppTec, Matrix Partners China, Boyu Capital, Sequoia Capital China, Temasek

Tech stack

CloudflareGoogle AnalyticsHstsHttp/3JqueryMicrosoft 365

Developer of therapeutics for various diseases. It offers a proprietary dual linker payload ADCs that are delivered to and concentrated in the tumor microenvironment, and bispecific dual payload ADCs that have the benefits of dual targeting that dilever two different MOA of payloads to cancel cells simultaneously.

Funding rounds

• Nov 2025Seed$60M

Founders & team

Siyi HuCo-FounderZhaoyuan ChenCo-Founder & CEOYanli MaoCo-Founder

Investors

Lapam Capital, Guofang Innovation, Jianxin Capital, Jifeng Ventures, Sino Biopharmaceutical, Decheng Capital

Developer of the NGS-based platform to detect cancer. The company has methylation haplotyping technology for detecting cancer biomarkers. Tumor cells release circulating tumor DNA (ctDNA) into the blood when undergoing apoptosis or necrosis and this ctDNA is detected as cancer biomarkers. The company has developed a PanSeer assay that measures distinct tumor-specific methylation patterns in adjacent methylation sites. It can detect cancer up to four years before conventional diagnosis.

Provider of NK cell therapy for treating cancer, cellular drugs to precisely target of tumors and tumor immune microenvironment (TIME)

Developer of immuno-oncology drugs for treating cancer and autoimmune diseases. The company has developed an in-house platform to generate monoclonal antibodies through hybridoma and phage display technologies. The company's product line include Olamkicept used for treating ulcerative colitis, TJ202 for Multiple myeloma / Autoimmune diseases, TJ101 for pediatric growth hormone deficiency, TJ301 for Ulcerative colitis / Auto-immune disease, Enoblituzumab for T cell activation combined with tumor-killing, etc.

Funding rounds

• Feb 2024Post IPO$69.9M
• Sep 2020Post IPO$418M
• Jun 2018Series C$220M
• Mar 2017Series B$150M

Founders & team

Yan JingwuChairman & CEO

Investors

Hillhouse, GIC, Alyeska Investment Group, Sphera Global Healthcare, Perceptive Advisors, Orbimed

Developer of drugs for the treatment of cancer. The company's products include TY-9591 is used to treat brain metastasis, TY-302 is used to treat solid tumours and ovarian cancer, TY-2136 is used for NSCLC, and TY-1036 is for MTC and NSCLC. These drugs can also be used with the combination of other drugs to treat cancer and other solid tumours.

Funding rounds

• Dec 2023Series D—
• Jan 2022Series C$51.7M
• May 2021Series B$62.1M
• Dec 2020Series B$39.8M

Founders & team

Wu YushengFounder & CEO

Investors

Guohai Innovation Capital Investment Management, Zhejiang Haibang Investment Management, ZSVC, Wenzhou State-owned Capital Investment and Operation, Huge Capital, Zhejiang Private Enterprise United Investment

Developer of CAR T cell therapies for the treatment of cancer. The company has developed a gene-editing platform to produce multiplex CAR T cell therapies such as FasTCAR, TruUCAR, and Donor-derived CAR for multiple myeloma, lymphoma, and leukemia. The company is also working on a combination of CAR-T with co-stimulatory factors.

Funding rounds

• Aug 2023Post IPO—
• Oct 2020Series C$100M
• Feb 2019Series B$85M
• Sep 2018Series A$10.2M

Founders & team

Wei CaoFounder & CEO

Investors

Lilly Asia Ventures, 6 Dimensions Capital, Temasek, Kingdon Capital Management, Vivo Capital, Adage Capital Management

Tech stack

Baidu Analytics (百度统计)BootstrapFlickityHammer.JsHugoJquery

Developer of reformulations for cancer treatment. The company's lead product candidate Liporaxel is used as an oral formulation for the treatment of cancer. Other products of the company include ON101 used for reducing wound inflammation, Lucitanib used for the treatment of cancer, etc.

Funding rounds

• Jul 2022Series B$14.8M
• Jul 2020Series B$171.3M
• Feb 2019Series A$146.6M

Founders & team

Ruiping DongCEO

Investors

Hillhouse, Yingke Capital, Elite Capital & Co, Huagai Capital, Cspc, CASVC

Tech stack

BootstrapCore-JsGoogle Font ApiJqueryOwl Carousel

Developer of cell therapy to treat solid tumours. The company uses Tumor Infiltration Lymphocytes (TIL) for the development of tumour immunotherapy. TIL is a tumour-specific killer T-cell which targets multiple tumour antigens in the tumour microenvironment.

Funding rounds

• Sep 2023Series B$60M
• Dec 2020Series A$15.3M

Founders & team

Liu YarongFounder & CEO

Investors

CICC, Qianhai Ark Asset Management, Yuanhe Capital, Sherpa Healthcare Partners, Decheng Capital, Matrix Partners China

CStone Pharma, a Shanghai-Suzhou startup, is developing and licensing novel drugs with a focus on immuno-oncology along with drugs for cardiovascular diseases, hematology and autoimmune diseases (e.g - rheumatoid arthritis). It has a robust oncology pipeline with eight assets in clinical stages. It is working on various targets including IDHm1, PDL-1, FGFR4, RET, PD-1, etc. The lead molecule, TIBSOVO has got FDA approval.